Antimicrobial Resistance Diagnostics Market Size, Share, Trends, Growth Outlook

Antimicrobial Resistance Diagnostics Market is estimated to increase at a growth rate of 6.9% CAGR over the forecast period from 2024 to 2030.

 

The Antimicrobial Resistance Diagnostics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (Microbiology Culture, Immunoassay, PCR, NGS, Mass Spectrometry, Rapid & Point of Care, Others), By Pathogen, Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS), Others), By End-User (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others).

 

An Introduction to Antimicrobial Resistance Diagnostics Market in 2024

The Antimicrobial Resistance (AMR) Diagnostics market in 2024 addresses the urgent global health threat posed by the emergence and spread of antimicrobial-resistant pathogens, offering advanced diagnostic solutions to support timely and targeted antimicrobial therapy decisions. AMR diagnostics encompass a range of molecular, phenotypic, and genotypic testing methods designed to detect and characterize antimicrobial resistance mechanisms in bacterial, fungal, and viral pathogens. By providing rapid and accurate identification of drug-resistant strains and informing antimicrobial stewardship practices, AMR diagnostics play a critical role in combating antibiotic overuse, reducing treatment failures, and preserving the effectiveness of existing antimicrobial agents. As healthcare systems worldwide confront the escalating challenges of antimicrobial resistance, the demand for innovative diagnostics technologies and surveillance tools continues to grow, driving investment and innovation in the AMR diagnostics market.

 

 

Antimicrobial Resistance Diagnostics Market Trend: Increasing Focus on Rapid and Accurate Diagnostics

A prominent trend in the Antimicrobial Resistance Diagnostics market is the increasing focus on developing rapid and accurate diagnostic solutions to combat antimicrobial resistance (AMR). With the rise of antibiotic-resistant pathogens posing a significant global health threat, there is a growing demand for diagnostic technologies capable of rapidly identifying resistant strains and guiding appropriate treatment decisions. Manufacturers are innovating to develop advanced diagnostic platforms, including molecular assays, phenotypic methods, and point-of-care tests, that can accurately detect antimicrobial resistance markers in clinical samples within minutes to hours. This trend reflects the urgent need for timely and targeted interventions to curb the spread of antimicrobial resistance and improve patient outcomes.

Antimicrobial Resistance Diagnostics Market Driver: Escalating Rates of Antimicrobial Resistance

A key driver in the Antimicrobial Resistance Diagnostics market is the escalating rates of antimicrobial resistance worldwide. Overuse and misuse of antibiotics in human healthcare, agriculture, and animal husbandry have contributed to the emergence and spread of resistant pathogens, rendering many conventional antimicrobial agents ineffective. Antimicrobial resistance not only leads to treatment failures and prolonged illnesses but also increases healthcare costs, morbidity, and mortality rates. As healthcare systems grapple with the growing threat of multidrug-resistant infections, there is a critical need for rapid and accurate diagnostic tools that can guide appropriate antimicrobial therapy, optimize antibiotic stewardship practices, and mitigate the impact of antimicrobial resistance on public health.

Antimicrobial Resistance Diagnostics Market Opportunity: Development of Multiplexed Diagnostic Platforms

One potential opportunity in the Antimicrobial Resistance Diagnostics market lies in the development of multiplexed diagnostic platforms capable of simultaneously detecting multiple resistance mechanisms and pathogens in clinical samples. By integrating various molecular targets and detection methods into a single assay, manufacturers can offer comprehensive diagnostic solutions that provide actionable insights into antimicrobial resistance profiles and guide personalized treatment strategies. Multiplexed diagnostics enable rapid identification of resistance patterns, differentiation between viral and bacterial infections, and determination of the most effective antibiotic regimen for individual patients. Moreover, by incorporating advanced bioinformatics tools and artificial intelligence algorithms, multiplexed platforms can enhance data analysis, interpretation, and clinical decision support, further optimizing antimicrobial therapy and antimicrobial stewardship efforts. Collaborative partnerships between diagnostic developers, healthcare providers, and regulatory agencies are essential to accelerate the adoption of multiplexed diagnostic technologies and address the evolving challenges posed by antimicrobial resistance.

 

Antimicrobial Resistance Diagnostics Market Segmentation

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

 

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

 

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Antimicrobial Resistance Diagnostics Market Companies

Abbott

Accelerate Diagnostics Inc

Becton, Dickinson and Company

bioMerieux

Danaher

F. Hoffmann-La Roche Ltd

Hologic Inc

Molsid

OpGen

Vela Diagnostics

Visby Medical Inc

*- List Not Exhaustive

 

Reasons to Buy the Antimicrobial Resistance Diagnostics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Antimicrobial Resistance Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Antimicrobial Resistance Diagnostics Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Antimicrobial Resistance Diagnostics Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Antimicrobial Resistance Diagnostics Market Size Outlook, $ Million, 2021 to 2030

3.2 Antimicrobial Resistance Diagnostics Market Outlook by Type, $ Million, 2021 to 2030

3.3 Antimicrobial Resistance Diagnostics Market Outlook by Product, $ Million, 2021 to 2030

3.4 Antimicrobial Resistance Diagnostics Market Outlook by Application, $ Million, 2021 to 2030

3.5 Antimicrobial Resistance Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Antimicrobial Resistance Diagnostics Market Industry

4.2 Key Market Trends in Antimicrobial Resistance Diagnostics Market Industry

4.3 Potential Opportunities in Antimicrobial Resistance Diagnostics Market Industry

4.4 Key Challenges in Antimicrobial Resistance Diagnostics Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Antimicrobial Resistance Diagnostics Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Antimicrobial Resistance Diagnostics Market Outlook By Segments

7.1 Antimicrobial Resistance Diagnostics Market Outlook by Segments

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

8 North America Antimicrobial Resistance Diagnostics Market Analysis And Outlook To 2030

8.1 Introduction to North America Antimicrobial Resistance Diagnostics Markets in 2024

8.2 North America Antimicrobial Resistance Diagnostics Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Antimicrobial Resistance Diagnostics Market size Outlook by Segments, 2021-2030

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

9 Europe Antimicrobial Resistance Diagnostics Market Analysis And Outlook To 2030

9.1 Introduction to Europe Antimicrobial Resistance Diagnostics Markets in 2024

9.2 Europe Antimicrobial Resistance Diagnostics Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Antimicrobial Resistance Diagnostics Market Size Outlook By Segments, 2021-2030

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

10 Asia Pacific Antimicrobial Resistance Diagnostics Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Antimicrobial Resistance Diagnostics Markets in 2024

10.2 Asia Pacific Antimicrobial Resistance Diagnostics Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Antimicrobial Resistance Diagnostics Market size Outlook by Segments, 2021-2030

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

11 South America Antimicrobial Resistance Diagnostics Market Analysis And Outlook To 2030

11.1 Introduction to South America Antimicrobial Resistance Diagnostics Markets in 2024

11.2 South America Antimicrobial Resistance Diagnostics Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Antimicrobial Resistance Diagnostics Market size Outlook by Segments, 2021-2030

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

12 Middle East And Africa Antimicrobial Resistance Diagnostics Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Antimicrobial Resistance Diagnostics Markets in 2024

12.2 Middle East and Africa Antimicrobial Resistance Diagnostics Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Antimicrobial Resistance Diagnostics Market size Outlook by Segments, 2021-2030

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

13 Company Profiles

13.1 Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Abbott

Accelerate Diagnostics Inc

Becton, Dickinson and Company

bioMerieux

Danaher

F. Hoffmann-La Roche Ltd

Hologic Inc

Molsid

OpGen

Vela Diagnostics

Visby Medical Inc

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Antimicrobial Resistance Diagnostics Market Segmentation

By Technology

Microbiology Culture

Immunoassay

PCR

NGS

Mass Spectrometry

Rapid & Point of Care

Others

 

By Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP)

Drug Resistant Campylobacter (DRC)

Clostridium Difficile (CD)

Methicillin Resistant Staphylococcus Aureus (MRSA)

Drug Resistant Neisseria Gonorrhoeae (DRNG)

Drug Resistant Salmonella (DRNTS)

Others

 

By End-user

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)